Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

ARS Pharmaceuticals (SPRY) Profit After Tax: 2021-2024

Historic Profit After Tax for ARS Pharmaceuticals (SPRY) over the last 4 years, with Dec 2024 value amounting to $8.0 million.

  • ARS Pharmaceuticals' Profit After Tax fell 167.41% to -$51.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$80.0 million, marking a year-over-year decrease of 63.00%. This contributed to the annual value of $8.0 million for FY2024, which is 114.71% up from last year.
  • Per ARS Pharmaceuticals' latest filing, its Profit After Tax stood at $8.0 million for FY2024, which was up 114.71% from -$54.4 million recorded in FY2023.
  • ARS Pharmaceuticals' 5-year Profit After Tax high stood at $8.0 million for FY2024, and its period low was -$54.4 million during FY2023.
  • For the 3-year period, ARS Pharmaceuticals' Profit After Tax averaged around -$27.0 million, with its median value being -$34.7 million (2022).
  • In the last 5 years, ARS Pharmaceuticals' Profit After Tax crashed by 71.33% in 2022 and then skyrocketed by 114.71% in 2024.
  • Over the past 4 years, ARS Pharmaceuticals' Profit After Tax (Yearly) stood at -$20.2 million in 2021, then crashed by 71.33% to -$34.7 million in 2022, then tumbled by 56.75% to -$54.4 million in 2023, then spiked by 114.71% to $8.0 million in 2024.